Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (noting a discrepancy with the metadata name "Cypherpunk Technologies Inc.") on May 3, 2018. The filing reports on the results of the Company's 2018 Annual Meeting of Stockholders held on the same date. The registrant is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding corporate governance and voting results rather than a financial statement.
Material Changes and Voting Results
The primary material event reported is the outcome of the stockholder vote at the Annual Meeting:
- Election of Directors: Two Class I director nominees were elected to serve until the 2021 annual meeting:
- James Cavanaugh: 9,935,331 votes For; 138,099 votes Withheld.
- John Littlechild: 9,938,021 votes For; 135,409 votes Withheld.
- Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified.
- Votes For: 13,462,175
- Votes Against: 13,516
- Votes Abstaining: 51,058
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the correct registrant name (Leap Therapeutics, Inc.) against the metadata provided.
- Confirm the tenure of the newly elected directors (Class I, until 2021).
- Review the full proxy statement for detailed biographies of the elected directors and the rationale for the auditor selection.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.